Can AI Predict FDA Decisions?
Three AI models. Real FDA drug approvals. Predictions locked in before decisions are announced. No cheating. No hindsight. Just forecasting skill.
62
FDA Events Tracked
27
Predictions Made
Models Compared
Next FDA Decision
6days(Feb 8)
Clemidsogene lanparvovec (RGX-121)
Regenxbio Inc • BLA
FDA decision on clemidsogene lanparvovec for the treatment of Mucopolysaccharidosis II (MPS II)
Gene Therapy - MPS II
Model Predictions
Claude
✓ Approve
GPT-5.2
✗ Reject
Grok
✓ Approve
FDA
Actual
Pending
AI Prediction Leaderboard
LEADING
Claude Opus 4.5
1/1 correct
100%
Avg. confidence: 81%
Grok 4
1/1 correct
100%
Avg. confidence: 92%
GPT-5.2
0/1 correct
0%
Avg. confidence: 78%
Each model gets the same trial data and research. Learn more →
Upcoming FDA Decisions
View all →Clemidsogene lanparvovec (RGX-121)
Regenxbio Inc
Feb 8•BLA▼
Claude
GPT
Grok
KEYTRUDA
Merck & Co Inc.
Feb 20•sBLA▼
Claude
GPT
Grok
INQOVI
Otsuka Holdings Co., Ltd.
Feb 25•sNDA▼
Claude
GPT
Grok
ET-600
Eton Pharmaceuticals, Inc
Feb 25•NDA▼
Claude
GPT
Grok
TransCon CNP
Ascendis Pharma A/S
Feb 28•NDA▼
Claude
GPT
Grok
| PDUFA Date | Drug | Indication | Type | FDA | Claude | GPT | Grok |
|---|---|---|---|---|---|---|---|
| Feb 8, 2026 | Clemidsogene lanparvovec (RGX-121) Regenxbio Inc | Gene Therapy - MPS II | BLA | PENDING | |||
| Feb 20, 2026 | KEYTRUDA Merck & Co Inc. | Oncology - Ovarian Cancer | sBLA | PENDING | |||
| Feb 25, 2026 | INQOVI Otsuka Holdings Co., Ltd. | Oncology - Leukemia | sNDA | PENDING | |||
| Feb 25, 2026 | ET-600 Eton Pharmaceuticals, Inc | Endocrinology - Diabetes Insipidus | NDA | PENDING | |||
| Feb 28, 2026 | TransCon CNP Ascendis Pharma A/S | Rare Disease - Achondroplasia | NDA | PENDING |
Past FDA Decisions
View all →Anaphylm
Aquestive Therapeutics Inc.
Jan 31•NDA▼
Claude
GPT
Grok
Leniolisib
Pharming Group N.V.
Jan 31•sNDA▼
Claude
GPT
Grok
| PDUFA Date | Drug | Indication | Type | FDA | Claude | GPT | Grok |
|---|---|---|---|---|---|---|---|
| Jan 31, 2026 | Anaphylm Aquestive Therapeutics Inc. | Allergy - Anaphylaxis | NDA | APPROVED | |||
| Jan 31, 2026 | Leniolisib Pharming Group N.V. | Rare Disease - PI3K Delta Syndrome | sNDA | APPROVED |